Acelrx Pharmaceuticals Inc., of Redwood City, Calif., was issued U.S. Patent No. 8,499,966, “Method of moving a delivery member of a dispensing device for administration of oral transmucosal dosage forms”; No. 8,535,714, “Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain”; and No. 8,548,623, “Storage and dispensing devices for administration of oral transmucosal dosage forms.”

Biolinerx Ltd., of Jerusalem, was issued a U.S. Patent notice of allowance for BL-5010, its product used in the nonsurgical removal of skin lesions.

Cellular Dynamics International Inc., of Madison, Wis., was issued U.S. Patent No. 8,546,140, “Methods for the Production of iPS Cells Using Non-Viral Approach.” The patent is related to reprogramming adult tissue cells, such as blood or skin, into induced pluripotent stem cells by inserting episomal vectors.

Discovery Laboratories Inc., of Warrington, Pa., was issued a U.S. Patent notice of allowance for No. 12/285,312, “Capillary System With Fluidic Element.” The patent is related to the company’s capillary aerosol generator technology for its Aerosurf program.

Geovax Labs Inc., of Atlanta, was issued a U.S. Patent notice of allowance No. 10/336,566, “Composition and Methods for Generating an Immune Response,” which was licensed from Emory University and the U.S. Government. The patent is related to the company’s DNA/MVA vaccine for HIV/AIDS.

Medicinova Inc., of San Diego, was issued a U.S. Patent notice of allowance for the company’s MN-029 (denibulin) di-hydrochloride, which covers the compound, pharmaceutical composition and method of treating certain cell proliferation diseases, including solid tumors.

Oncomed Pharmaceuticals Inc., of Redwood City, Calif., was issued U.S. Patent No. 8,551,715, for its MabTrap antibody display technology.